Cui Chen Peng Sun Jianting Long
10.3389/fimmu.2022.941092
Front Immunol
2022 Aug 2;13:941092.
case report durable response first-line treatment metastatic thymic carcinoma pembrolizumab
CC BY
https://pubmed.ncbi.nlm.nih.gov/35983052/
Carcinoma, Squamous Cell / drug therapy Thymoma / drug therapy Thymus Neoplasms / drug therapy
Carcinoma, Squamous Cell / drug therapy Thymoma / drug therapy Thymus Neoplasms / drug therapy Case Reports Research Support, Non-U.S. Gov't Antibodies, Monoclonal, Humanized B7-H1 Antigen / metabolism Humans Neoplasm Recurrence, Local Antibodies, Monoclonal, Humanized B7-H1 Antigen pembrolizumab
PMC9378774
35983052
Robust and durable response to first-line treatment of pembrolizumab combined with chemotherapy in two patients with metastatic thymic squamous cell carcinoma: Case report
2022